TRAX

TRAX has broken below key horizontal support and its short-term EMAs on rising volume, signaling seller control without oversold exhaustion. The former support now acts as resistance on any bounce, reinforcing a bearish medium-term bias in a Stage 3 distribution environment. Immediate sell execution is justified by the clear breakdown dynamics.

• ↑Positive clinical results drove shares from ~$19 to $41 (16.3% rally)
• ↑13F ownership ~82% indicates strong hedge-fund backing
• ↓Q2 net loss $50M and EPS –$1.45 underscore deep unprofitability